Plastic Surgery – Derma

2006 May
Aging, inflammation and cancer.
Aging is a key aspect of neoplasia at the level of cells, individuals and populations.

Ortho

2006 May
Stem cells for the repair and regeneration of bone
There continues to be a need for novel therapies directed at bone repair and regeneration in modern orthopaedics.

Pulmonary Disease

2018 November
Off-label mesenchymal stromal cell treatment in two infants with severe bronchopulmonary dysplasia: clinical course and biomarkers profile
Bronchopulmonary dysplasia (BPD) is the most prevalent sequelae of premature birth, for which therapeutic options are currently limited.
2018 November
Mesenchymal Stem Cells for the Treatment of Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is an inexorably progressive lung disease of unknown origin
2018 November
Mesenchymal stromal cells: a novel therapy for the treatment of chronic obstructive pulmonary disease?
COPD is characterised by tissue destruction and inflammation.
2018 April
Mesenchymal stromal cell infusion modulates systemic immunological responses in stable COPD patients: A phase I pilot study
COPD is characterised by tissue destruction and inflammation. Given the lack of curative treatments and the progressive nature of the disease, new treatments for COPD are highly relevant.
2018 April
Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema
We sought to assess whether the effects of mesenchymal stromal cells (MSC) on lung inflammation and remodeling in experimental emphysema would differ according to MSC source and administration route.
2018 April
Combined Bone Marrow‐Derived Mesenchymal Stromal Cell Therapy and One‐Way Endobronchial Valve Placement in Patients with Pulmonary Emphysema: A Phase I Clinical Trial
One‐way endobronchial valves (EBV) insertion to reduce pulmonary air trapping has been used as therapy for chronic obstructive pulmonary disease (COPD) patients.
2017 August
Autologous Stromal Vascular Fraction in the Intravenous Treatment of End-Stage Chronic Obstructive Pulmonary Disease: A Phase I Trial of Safety and Tolerability
Chronic obstructive pulmonary disease (COPD) is a consistently progressive, ultimately fatal disease for which no treat- ment exists capable of either reversing or even interrupting its course.
2016 January
A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema
Mesenchymal stromal cells (MSCs) may reduce inflammation and promote tissue repair in pulmonary emphysema.
2016 January
Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition
Ageing is characterised by an increase in the concentration of inflammatory markers in the bloodstream, a phenomenon that has been termed “inflammageing”. The inflammatory response is beneficial as an acute, transient reaction to harmful conditions, facilitating the defence, repair, turnover and adaptation of many tissues. However, chronic and low grade inflammation is likely to be detrimental for many tissues and for normal functions.
2016 January
Therapeutic potential of products derived from mesenchymal stem/stromal cells in pulmonary disease
The increasingly high rates of morbidity and mortality due to acute and chronic lung diseases have emerged as one of the major public health issues globally.
2018 October
Clinical Application of Mesenchymal Stem Cell-Derived Extracellular Vesicle-Based Therapeutics for Inflammatory Lung Diseases
It is currently thought that extracellular vesicles (EVs), such as exosomes and microvesicles, play an important autocrine/paracrine role in intercellular communication.
2018 October
Clinical observation of umbilical cord mesenchymal stem cell treatment of severe idiopathic pulmonary fibrosis: A case report
Idiopathic pulmonary fibrosis (IPF) is a degenerative disease characterized by fibrosis.
2017 July
Mesenchymal Stem Cells in Fibrotic Disease
Fibrosis is associated with organ failure and high mortality and is commonly characterized by aberrant myofibroblast accumulation.
2018 July
Mesenchymal Stem Cell Therapy of Pulmonary Fibrosis: Improvement with Target Combination
Although the clinical application of new drugs has been shown to be effective in slowing disease progression and improving the quality of life in patients with pulmonary fibrosis, the damaged lung tissue does not recover with these drugs.
2018 July
Clinical applications of mesenchymal stem cells in chronic lung diseases
Mesenchymal stem (stromal) cells (MSCs) are multipotent stromal cells that have the ability to modulate immune response to tissue injury and promote repair in vivo.
2017 May
Mesenchymal stem cells in idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a major cause of respiratory failure in critically ill patients and common outcome of various lung interstitial diseases.
2018 August
Cell Therapy in Idiopathic Pulmonary Fibrosis
diopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options.
2018 September
Human Mesenchymal Stem Cell Secretome from Bone Marrow or Adipose-Derived Tissue Sources for Treatment of Hypoxia-Induced Pulmonary Epithelial Injury
Alveolar epithelial dysfunction induced by hypoxic stress plays a significant role in the pathological process of lung ischemia-reperfusion injury (IRI).
2018 April
Transplantation of adipose-derived mesenchymal stem cells attenuates pulmonary fibrosis of silicosis via anti-inflammatory and anti-apoptosis effects in rats
Silicosis has been topping the list of high-incidence occupational diseases in developing countries and cannot be completely cured.

Anti-Ageing

2006 May
Dermatologic Surgery Volume 32
Improvement in the appearance of wrinkles with topical transforming growth factor β1 and L-ascorbic acid